Needham Reiterates Buy on Viridian Therapeutics, Maintains $47 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a price target of $47.
July 11, 2023 | 10:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Viridian Therapeutics and maintained a price target of $47.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $47 price target indicates a positive outlook for Viridian Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100